129 related articles for article (PubMed ID: 28825794)
1. Nanofitin as a New Molecular-Imaging Agent for the Diagnosis of Epidermal Growth Factor Receptor Over-Expressing Tumors.
Goux M; Becker G; Gorré H; Dammicco S; Desselle A; Egrise D; Leroi N; Lallemand F; Bahri MA; Doumont G; Plenevaux A; Cinier M; Luxen A
Bioconjug Chem; 2017 Sep; 28(9):2361-2371. PubMed ID: 28825794
[TBL] [Abstract][Full Text] [Related]
2. Regiospecific radiolabelling of Nanofitin on Ni magnetic beads with [
Dammicco S; Goux M; Lemaire C; Becker G; Bahri MA; Plenevaux A; Cinier M; Luxen A
Nucl Med Biol; 2017 Aug; 51():33-39. PubMed ID: 28575696
[TBL] [Abstract][Full Text] [Related]
3. PET of EGFR expression with an 18F-labeled affibody molecule.
Miao Z; Ren G; Liu H; Qi S; Wu S; Cheng Z
J Nucl Med; 2012 Jul; 53(7):1110-8. PubMed ID: 22689926
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of four affibody-based near-infrared fluorescent probes for optical imaging of epidermal growth factor receptor positive tumors.
Qi S; Miao Z; Liu H; Xu Y; Feng Y; Cheng Z
Bioconjug Chem; 2012 Jun; 23(6):1149-56. PubMed ID: 22621238
[TBL] [Abstract][Full Text] [Related]
5. PET imaging of EGF receptors using [18F]FBEM-EGF in a head and neck squamous cell carcinoma model.
Li W; Niu G; Lang L; Guo N; Ma Y; Kiesewetter DO; Backer JM; Shen B; Chen X
Eur J Nucl Med Mol Imaging; 2012 Feb; 39(2):300-8. PubMed ID: 22109665
[TBL] [Abstract][Full Text] [Related]
6. Comparison of two site-specifically (18)F-labeled affibodies for PET imaging of EGFR positive tumors.
Su X; Cheng K; Jeon J; Shen B; Venturin GT; Hu X; Rao J; Chin FT; Wu H; Cheng Z
Mol Pharm; 2014 Nov; 11(11):3947-56. PubMed ID: 24972326
[TBL] [Abstract][Full Text] [Related]
7. Small-animal PET imaging of human epidermal growth factor receptor positive tumor with a 64Cu labeled affibody protein.
Miao Z; Ren G; Liu H; Jiang L; Cheng Z
Bioconjug Chem; 2010 May; 21(5):947-54. PubMed ID: 20402512
[TBL] [Abstract][Full Text] [Related]
8. Conjugation with (111)In-DTPA-poly(ethylene glycol) improves imaging of anti-EGF receptor antibody C225.
Wen X; Wu QP; Ke S; Ellis L; Charnsangavej C; Delpassand AS; Wallace S; Li C
J Nucl Med; 2001 Oct; 42(10):1530-7. PubMed ID: 11585869
[TBL] [Abstract][Full Text] [Related]
9. [18F]FBEM-Z(HER2:342)-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography.
Kramer-Marek G; Kiesewetter DO; Martiniova L; Jagoda E; Lee SB; Capala J
Eur J Nucl Med Mol Imaging; 2008 May; 35(5):1008-18. PubMed ID: 18157531
[TBL] [Abstract][Full Text] [Related]
10. PET of insulinoma using ¹⁸F-FBEM-EM3106B, a new GLP-1 analogue.
Gao H; Niu G; Yang M; Quan Q; Ma Y; Murage EN; Ahn JM; Kiesewetter DO; Chen X
Mol Pharm; 2011 Oct; 8(5):1775-82. PubMed ID: 21800885
[TBL] [Abstract][Full Text] [Related]
11. Molecular imaging reveals trastuzumab-induced epidermal growth factor receptor downregulation in vivo.
Ma T; Sun X; Cui L; Gao L; Wu Y; Liu H; Zhu Z; Wang F; Liu Z
J Nucl Med; 2014 Jun; 55(6):1002-7. PubMed ID: 24732154
[TBL] [Abstract][Full Text] [Related]
12. Tumor targeting using anti-epidermal growth factor receptor (ior egf/r3) immunoconjugate with a tetraaza macrocyclic agent (DO3A-EA).
Mishra G; Panwar P; Mishra AK
Mol Imaging; 2012; 11(5):408-16. PubMed ID: 22954185
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and evaluation of [
Li X; Hu K; Liu W; Wei Y; Sha R; Long Y; Han Y; Sun P; Wu H; Li G; Tang G; Huang S
Nucl Med Biol; 2020; 90-91():84-92. PubMed ID: 33189948
[TBL] [Abstract][Full Text] [Related]
14. PET imaging of epidermal growth factor receptor expression in tumours using 89Zr-labelled ZEGFR:2377 affibody molecules.
Garousi J; Andersson KG; Mitran B; Pichl ML; Ståhl S; Orlova A; Löfblom J; Tolmachev V
Int J Oncol; 2016 Apr; 48(4):1325-32. PubMed ID: 26847636
[TBL] [Abstract][Full Text] [Related]
15. Targeted Nanofitin-drug Conjugates Achieve Efficient Tumor Delivery and Therapeutic Effect in an EGFRpos Mouse Xenograft Model.
Huet S; Zeisser Labouebe M; Castro R; Jacquot P; Pedrault J; Viollet S; Van Simaeys G; Doumont G; Larbanoix L; Zindy E; Cunha AE; Scapozza L; Cinier M
Mol Cancer Ther; 2023 Nov; 22(11):1343-1351. PubMed ID: 37578807
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors.
Abourbeh G; Dissoki S; Jacobson O; Litchi A; Ben Daniel R; Laki D; Levitzki A; Mishani E
Nucl Med Biol; 2007 Jan; 34(1):55-70. PubMed ID: 17210462
[TBL] [Abstract][Full Text] [Related]
17. In vivo diagnosis of epidermal growth factor receptor expression using molecular imaging with a cocktail of optically labeled monoclonal antibodies.
Barrett T; Koyama Y; Hama Y; Ravizzini G; Shin IS; Jang BS; Paik CH; Urano Y; Choyke PL; Kobayashi H
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6639-48. PubMed ID: 17982120
[TBL] [Abstract][Full Text] [Related]
18. Immuno-PET quantitation of de2-7 epidermal growth factor receptor expression in glioma using 124I-IMP-R4-labeled antibody ch806.
Lee FT; O'Keefe GJ; Gan HK; Mountain AJ; Jones GR; Saunder TH; Sagona J; Rigopoulos A; Smyth FE; Johns TG; Govindan SV; Goldenberg DM; Old LJ; Scott AM
J Nucl Med; 2010 Jun; 51(6):967-72. PubMed ID: 20484439
[TBL] [Abstract][Full Text] [Related]
19. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET.
Aerts HJ; Dubois L; Perk L; Vermaelen P; van Dongen GA; Wouters BG; Lambin P
J Nucl Med; 2009 Jan; 50(1):123-31. PubMed ID: 19091906
[TBL] [Abstract][Full Text] [Related]
20.
Kruziki MA; Case BA; Chan JY; Zudock EJ; Woldring DR; Yee D; Hackel BJ
Mol Pharm; 2016 Nov; 13(11):3747-3755. PubMed ID: 27696863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
